BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078340" target="_blank" >RIV/00216224:14110/14:00078340 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/14:00061820
Result on the web
<a href="http://dx.doi.org/10.1002/ajh.23794" target="_blank" >http://dx.doi.org/10.1002/ajh.23794</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ajh.23794" target="_blank" >10.1002/ajh.23794</a>

Result language
angličtina
Original language name
BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing
Original language description
Mutations in the BCR-ABL1 kinase domain (KD) represent one of the most important causes of resistance to tyrosine kinase inhibitors (TKIs) treatment in patients with chronic myeloid leukemia (CML). The resistance-causing mutations are hypothesized to expand directly from the stem and/or progenitor cells and are present in CD341 cells significantly earlier than they occur in bone marrow or peripheral blood. Thus, early detection of these mutations is of great importance, since it can affect the subsequent TKI therapy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/EE2.3.30.0037" target="_blank" >EE2.3.30.0037: Employment of Best Young Scientists for International Cooperation Empowerment</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)